UCSF/Zuckerberg San Francisco General Hospital
Welcome,         Profile    Billing    Logout  
 19 Trials 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Deeks, Steven G
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Active, not recruiting
2
40
US
Ensitrelvir, ensitrelvir fumaric acid, Placebo
Timothy Henrich, Shionogi Inc.
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
06/25
12/25
NCT03684655: Imaging Immune Activation in HIV by PET-MR

Recruiting
2
30
US
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT
CellSight Technologies, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
HIV Infections
10/25
11/25
outSMART-LC, NCT05877508: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Active, not recruiting
2
36
US
AER002, Placebo
Michael Peluso, MD, Aerium Therapeutics, Patient-Led Research Collaborative, PolyBio Research Foundation
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
07/24
07/25
CLEAR HIV, NCT05488431: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial ( Trial)

Recruiting
2
121
US
Bempedoic acid, BA, Placebo
Priscilla Hsue, MD, University of California, Los Angeles, Massachusetts General Hospital
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
03/28
03/28
CONTENDER, NCT06810934: A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

Not yet recruiting
1/2
80
NA
CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo
Kara Chew, University of California, San Francisco, University of California, Davis, Tendel Therapies, Inc.
COVID-19
04/27
03/29
NCT04648046: CAR-T Cells for HIV Infection

Recruiting
1/2
18
US
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Steven Deeks, Caring Cross
HIV Infections
12/27
12/28
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR

Recruiting
1
10
US
18F-Raltegravir
University of California, San Francisco, Merck Sharp & Dohme LLC
HIV-1-infection
11/24
01/25
SCOPE-ATI, NCT04359186: SCOPE Analytic Treatment Interruption Protocol

Recruiting
N/A
40
US
Treatment Interruption Arm
University of California, San Francisco, Chan Zuckerberg Biohub
HIV/AIDS
06/25
06/26
NCT05172024: Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

Active, not recruiting
N/A
15178
US
NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI)
SARS-CoV2 Infection
04/25
05/25
LIINC, NCT04362150: Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Recruiting
N/A
800
US
University of California, San Francisco
COVID
12/25
12/25
NCT01336855: Collection of Blood for Multiple Collaborative Studies

Recruiting
N/A
2000
US
University of California, San Francisco
HIV
01/30
01/30
NCT01202305: The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

Recruiting
N/A
50
US
Lymph node biopsy
University of California, San Francisco, National Institutes of Health (NIH)
HIV
04/30
04/30
NCT00187512: SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Recruiting
N/A
2500
US
University of California, San Francisco, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/32
12/33
NCT01161199: The Use of Leukapheresis to Support HIV Pathogenesis Studies

Recruiting
N/A
100
US
Leukapheresis
University of California, San Francisco
HIV
07/33
07/33
Hsue, Priscilla
REVERSE-LC, NCT05858515: REVERSE-Long COVID-19 With Baricitinib Study

Withdrawn
3
550
US
Baricitinib 4 MG, Olumiant, Placebo
Vanderbilt University Medical Center, Emory University, University of California, San Francisco, University of Minnesota, Vanderbilt University, Yale University
Post-Acute COVID-19 Syndrome
12/27
12/29
EPIC-HIV, NCT03207945: Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection ( Study)

Recruiting
3
140
US
Alirocumab, Sar236553/REG727, Placebo
University of California, San Francisco, Massachusetts General Hospital
Dyslipidemias, Cardiovascular Diseases, HIV Infections
07/24
07/25
NCT02272946: Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Completed
2
43
US
Canakinumab, IL--1β, Placebo
Priscilla Hsue, MD, Massachusetts General Hospital
HIV, Cardiovascular Disease
02/21
12/21
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Active, not recruiting
2
40
US
Ensitrelvir, ensitrelvir fumaric acid, Placebo
Timothy Henrich, Shionogi Inc.
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
06/25
12/25
NCT06029712: Heart Failure Polypill at a Safety Net Hospital

Active, not recruiting
2
35
US
Heart failure polypill, Control Rx
University of California, San Francisco, UCSF CAPS-HIV Innovative Grant, UCSF CFAR-ARI HIV Boost Award, ACC/ABC Merck Research Fellowship Award (support for Dr. DeJong)
Heart Failure With Reduced Ejection Fraction, HIV Infections
09/24
12/24
outSMART-LC, NCT05877508: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Active, not recruiting
2
36
US
AER002, Placebo
Michael Peluso, MD, Aerium Therapeutics, Patient-Led Research Collaborative, PolyBio Research Foundation
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
07/24
07/25
CLEAR HIV, NCT05488431: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial ( Trial)

Recruiting
2
121
US
Bempedoic acid, BA, Placebo
Priscilla Hsue, MD, University of California, Los Angeles, Massachusetts General Hospital
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
03/28
03/28
Henrich, Timothy
NCT04083170: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Terminated
2
1
US
Fludarabine, 118218, 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, 9-Beta-D-arabinofuranosyl-2-fluoroadenine, Fluradosa, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Thiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thiofosfamide, Thio-Tepa, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, Triethylene thiophosphoramide, Triethylenethiophosphoramide, TSPA, WR 45312, Total-Body Irradiation, TBI, TOTAL BODY IRRADIATION, Whole Body Irradiation, Whole-Body Irradiation, SCT_TBI, Umbilical Cord Blood Transplantation, Cord Blood Transplantation, UCB transplantation, Dilanubicel, Allogeneic UCB-derived Hematopoietic Stem and Progenitor Cells NLA101, Allogeneic Umbilical Cord Blood-derived HSPCs NLA101, NLA101
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Refractory Anemia
11/22
11/22
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Active, not recruiting
2
40
US
Ensitrelvir, ensitrelvir fumaric acid, Placebo
Timothy Henrich, Shionogi Inc.
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
06/25
12/25
NCT03684655: Imaging Immune Activation in HIV by PET-MR

Recruiting
2
30
US
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT
CellSight Technologies, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
HIV Infections
10/25
11/25
NCT04815096: Imaging Immune Activation in COVID-19

Recruiting
2
80
US
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT
CellSight Technologies, Inc., University of California, San Francisco
Covid19, SARS-CoV Infection
10/25
10/25
outSMART-LC, NCT05877508: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Active, not recruiting
2
36
US
AER002, Placebo
Michael Peluso, MD, Aerium Therapeutics, Patient-Led Research Collaborative, PolyBio Research Foundation
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
07/24
07/25
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR

Recruiting
1
10
US
18F-Raltegravir
University of California, San Francisco, Merck Sharp & Dohme LLC
HIV-1-infection
11/24
01/25
NCT05244473: A Safety Study of Brentuximab Vedotin in Participants With HIV

Withdrawn
1
48
US
brentuximab vedotin, ADCETRIS, Placebo, ART
Seagen Inc.
Human Immunodeficiency Virus
05/24
05/24
NCT03729752: PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

Recruiting
1
30
US
[89]Zr-DFO-VRC-HIVMAB060-00-AB, [89]Zr-DFO-VRC01
University of California, San Francisco, amfAR, The Foundation for AIDS Research
HIV-1-infection
10/24
01/25
Peluso, Michael J
RECOVER-VITAL, NCT05595369: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Active, not recruiting
2
964
US
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Kanecia Obie Zimmerman
Long COVID, Long Covid19
08/24
03/25
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Active, not recruiting
2
40
US
Ensitrelvir, ensitrelvir fumaric acid, Placebo
Timothy Henrich, Shionogi Inc.
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
06/25
12/25
outSMART-LC, NCT05877508: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Active, not recruiting
2
36
US
AER002, Placebo
Michael Peluso, MD, Aerium Therapeutics, Patient-Led Research Collaborative, PolyBio Research Foundation
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
07/24
07/25
LIINC, NCT04362150: Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Recruiting
N/A
800
US
University of California, San Francisco
COVID
12/25
12/25

Download Options